MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.nmd.2019.09.007

Медицинская библиотека · Neuromuscular disorders : NMD · 2019

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.

De Vivo Darryl C, Bertini Enrico, Swoboda Kathryn J, Hwu Wuh-Liang, Crawford Thomas O, Finkel Richard S, Kirschner Janbernd, Kuntz Nancy L, Parsons Julie A, Ryan Monique M, Butterfield Russell J, Topaloglu Haluk, Ben-Omran Tawfeg, Sansone Valeria A, Jong Yuh-Jyh, Shu Francy, Staropoli John F, Kerr Douglas, Sandrock Alfred W, Stebbins Christopher, Petrillo Marco, Braley Gabriel, Johnson Kristina, Foster Richard, Gheuens Sarah, Bhan Ishir, Reyna Sandra P, Fradette Stephanie, Farwell Wildon, NURTURE Study Group

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Spinal muscular atrophy (SMA) is a neurodegenerative disease associated with severe muscle atrophy and weakness in the limbs and trunk. We report interim efficacy and safety outcomes as of March 29, 2019 in 25 children with genetically diagnosed SMA who first received nusinersen in infancy while presymptomatic in the ongoing Phase 2, multisite, open-label, single-arm NURTURE trial. Fifteen children have two SMN2 copies and 10 have three SMN2 copies. At last visit, children were median (range) 34.8 [25.7-45.4] months of age and past the expected age of symptom onset for SMA Types I or II; all were alive and none required tracheostomy or permanent ventilation. Four (16%) participants with two SMN2 copies utilized respiratory support for ≥6 h/day for ≥7 consecutive days that was initiated during acute, reversible illnesses. All 25 participants achieved the ability to sit without support, 23/25 (92%) achieved walking with assistance, and 22/25 (88%) achieved walking independently. Eight infants had adverse events considered possibly related to nusinersen by the study investigators. These results, representing a median 2.9 years of follow up, emphasize the importance of proactive treatment with nusinersen immediately after establishing the genetic diagnosis of SMA in presymptomatic infants and emerging newborn screening efforts.

Для цитирования: De Vivo Darryl C, Bertini Enrico, Swoboda Kathryn J, Hwu Wuh-Liang, Crawford Thomas O, Finkel Richard S, Kirschner Janbernd, Kuntz Nancy L, Parsons Julie A, Ryan Monique M, Butterfield Russell J, Topaloglu Haluk, Ben-Omran Tawfeg, Sansone Valeria A, Jong Yuh-Jyh, Shu Francy, Staropoli John F, Kerr Douglas, Sandrock Alfred W, Stebbins Christopher, Petrillo Marco, Braley Gabriel, Johnson Kristina, Foster Richard, Gheuens Sarah, Bhan Ishir, Reyna Sandra P, Fradette Stephanie, Farwell Wildon, NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.. Neuromuscular disorders : NMD. 2019. DOI: 10.1016/j.nmd.2019.09.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.